Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Commonalities"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
product_txtF_mv:"National Center for Biotechnology Information"
Showing
1
-
20
of
790
Search:
'"Commonalities"'
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Darunavir/Cobicistat (Prezcobix)
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
2
Aripiprazole (Abilify) : depression, major depressive disorder (MDD)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
3
Fluticasone furoate/Vilanterol (Breo ellipta)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
4
Galsulfase (Naglazyme)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
5
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) (Genvoya) fixed-dose combination, oral tablet
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
6
Mepolizumab (Nucala)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
7
Rivaroxaban (Xarelto) : treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE.
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
8
OnabotulinumtoxinA for injection (Botox) for the prophylaxis of headaches in adults with chronic migraine ([equal to or greater than] 15 days per month with headache lasting 4 hour...
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
9
Riociguat (Adempas) : management of inoperable chronic thromboembolic pulmonary hypertension
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
10
Golimumab (Simponi) IV : in combination with methotrexate (MTX) for the treatment of adult patients with moderately to severely active rheumatoid arthritis
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
11
Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
12
Standardized allergenic extract, timothy grass (phleum pratense) (GRASTEK) (sublingual tablet 2,800 BAU)
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
13
Fluticasone furoate/Vilanterol (Breo ellipta)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
14
Canakinumab (Ilaris)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
15
Simeprevir (Galexos) (150 mg)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
16
Alogliptin (Nesina) for type 2 diabetes mellitus
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
17
CADTH Canadian Drug Expert Committee final recommendation: Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.) : indication : type 2 diabetes mel...
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
18
Tocilizumab (Actemra) : adult patients with moderately to severely active rheumatoid arthritis
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
19
Galsulfase (Naglazyme)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
20
CDEC final recommendation: Dolutegravir (Tivicay -- ViiV Healthcare ULC) : indication : HIV infection
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
1
2
3
4
5
6
7
8
9
10
11
Back
Narrow Search
Remove Filters
Clear Filter
Collection: National Center for Biotechnology Information
Year of Publication
From:
To:
Classification
610 - Medicine & health
581
330 - Economics
256
140 - Specific philosophical schools
83
700 - The arts; fine & decorative arts
76
580 - Plants (Botany)
11
380 - Commerce, communications & transportation
7
more ...
615 - Pharmacology & therapeutics
4
see all ...
less ...
Language
English
790
Collection
National Center for Biotechnology Information
Author
Canadian Agency for Drugs and Technologies in Health
729
CADTH Canadian Drug Expert Committee
210
Canadian Diabetes Association
4
Kidney Foundation of Canada
2
Multiple Sclerosis Society of Canada
2
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=product_txtF_mv%3A%22National+Center+for+Biotechnology+Information%22&lookfor=%22Commonalities%22&type=Series
Send by Email
×
Loading...